PAI-1 as a target to protect mothers’ blood vessels in preeclampsia
Official title: Plasminogen activator inhibitor 1 (PAI1) as a therapeutic target for maternal endothelial dysfunction in preeclampsia
Funded at Yale University · NIH-11378715 · Data updated 2026-11-12
A study at Yale aims to see if blocking a molecule called PAI-1 can help protect a pregnant person’s blood vessels and reduce complications in preeclampsia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | August 1, 2025 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $767,056 |
| NIH project number | 5R01HL181577-02 |
| Project ID | NIH-11378715 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant people at risk for or diagnosed with preeclampsia who would be eligible for related clinical work or future trials.
✕Less likely to help
Pregnant people without preeclampsia or those not connected to related clinical studies may not receive direct benefit.
What this research studies
Preeclampsia is a dangerous pregnancy condition that can raise blood pressure and harm organs. This project focuses on the molecule PAI-1, which is higher in preeclampsia and may contribute to blood vessel problems. Researchers will explore how PAI-1 affects blood vessels and whether targeting it could improve maternal outcomes. The work combines lab studies and analyses that may point toward new therapies to prolong safe pregnancies and protect both mother and baby.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that improve blood vessel function and reduce risks for mothers and babies during pregnancy.
How similar studies have gone: Previous research supports a link between PAI-1 and endothelial dysfunction, but translating this to therapy in preeclampsia is still being explored.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Mcadow, Molly E — Yale University
- Study coordinator: Mcadow, Molly E
Related research
Other NIH-funded projects on the same topics.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Endothelial dysfunction in Alzheimer’s disease: a data-driven model for diagnosis and prognosis
This research explores brain blood vessel problems in people with Alzheimer’s to find new biomarkers that could help diagnose and predict progression.
-
Environmental air pollutants linked to preeclampsia risk in pregnancy
This study looks at whether common air pollutants called PAHs increase the risk of preeclampsia during pregnancy.
-
Dynamic risk prediction and subtyping of hypertensive disorders in pregnancy
A digital health approach uses AI to spot early warning signs of preeclampsia and gestational hypertension from pregnancy data, so clinicians can tailor care for pregnant people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.